Related Experiment Video
Updated: Aug 5, 2026
13:48
Reverse Genetics Mediated Recovery of Infectious Murine Norovirus
Published on: June 24, 2012
Treatment With Ruxolitinib and TAK-779 Enhances GII.17 Human Norovirus Replication and Enables Serial Passaging in
Eri Hiraishi1,2, Tsuyoshi Hayashi3, Yoshiki Fujii3
1Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms
|August 1, 2026
Summary
Blocking interferon response and chemokine signaling pathways enhances human norovirus (HuNoV) replication in lab settings. This discovery aids in generating higher-titer viral stocks for research.
Area of Science:
- Virology
- Immunology
- Gastroenterology
Background:
- Human norovirus (HuNoV) causes significant acute viral gastroenteritis globally.
- Current in vitro replication methods using human intestinal enteroids (HIEs) face challenges with low viral titers and passage efficiencies.
- Interferon response and chemokine signaling are suspected host pathways limiting efficient HuNoV replication.
Purpose of the Study:
- To investigate the impact of inhibiting interferon and chemokine pathways on HuNoV replication in HIEs.
- To determine if specific inhibitors can enhance viral replication for laboratory stock generation.
Main Methods:
- Utilized wild-type jejunal HIEs for in vitro HuNoV replication studies.
- Administered ruxolitinib (a JAK 1/JAK2 inhibitor) and TAK-779 (a CXCR3/CCR5/CCR2 antagonist) individually and in combination.
- Quantified GII.17 HuNoV replication levels at 48 and 96 hours postinfection (hpi) compared to DMSO controls.
Main Results:
- TAK-779 alone significantly increased GII.17 HuNoV replication (2.3-fold at 48 hpi, 6.0-fold at 96 hpi).
- Ruxolitinib alone showed no significant effect on viral replication.
- Combined treatment with TAK-779 and ruxolitinib markedly enhanced GII.17 HuNoV replication (6.0-fold at 48 hpi, 10.7-fold at 96 hpi), enabling serial passaging.
Conclusions:
- Simultaneous inhibition of interferon and chemokine signaling pathways significantly boosts GII.17 HuNoV replication in HIEs.
- This combined inhibition strategy facilitates the generation of high-titer HuNoV laboratory stocks.
- Targeting these host pathways offers a promising approach for improved in vitro norovirus research.
Related Concept Videos
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...